A rare variant of primary ciliary dyskinesia in combination with hereditary hemorrhagic telangiectasia type 1: a case from practice

Primary ciliary dyskinesia (PCD) is a rare genetic disease belonging to the group of ciliopathies. The disease develops because a defect in the ultrastructure of the epithelial cilia in the respiratory tract and similar structures (sperm flagella, villi of the fallopian tubes, ventricular ependyma, etc.) disturbs their motor function. Currently, various clinical and genetic variants of the disease are distinguished, increasing the effectiveness of dynamic examination and treatment.

Aim. In this article, we describe a patient with a rare variant of PCD that we identified in combination with a mutation in the ENG gene responsible for the development of hereditary hemorrhagic telangiectasia type 1 (HHT-1). HHT-1 is a rare hereditary disease that manifests as various vascular dysplasias, including arteriovenous malformations (AVM) in the lungs, which can significantly worsen the course of the disease and be a predictor of an unfavorable outcome.

Conclusion. The presented case demonstrates a combination of two rare genetic diseases in a child. The uniqueness of the case also lies in the fact that the identified rare mutation in the DRC1 gene responsible for the development of PCD is not associated with a loss of motility of the cilia of the ciliated epithelium, which makes the testing and the correct diagnosis even more difficult.

1. Novak A.A., Mizernitskiy Yu.L. [Primary ciliary dyskinesia: state of the problem and prospects]. Meditsinskiy sovet. 2021; (1): 276-285. DOI: 10.21518/2079-701X-2021-1-276-285 (in Russian).

2. Bequignon E., Dupuy L., Zerah-Lancner F. et al. Critical evaluation of sinonasal disease in 64 adults with primary ciliary dyskinesia. J. Clin. Med. 2019; 8 (5): 619. DOI: 10.3390/jcm8050619.

3. Bush A., Hogg C. Primary ciliary dyskinesia: recent advances in epidemiology, diagnosis, management and relationship with the expanding spectrum of ciliopathy. Expert Rev. Respir. Med. 2012; 6 (6): 663-682. DOI: 10.1586/ers.12.60.

4. Fliegauf M., Olbrich H., Horvath J. et al. Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. Am. J. Respir. Crit. Care Med. 2005; 171 (12): 1343-1349. DOI: 10.1164/rccm.200411-1583OC.

5. Fretzayas A., Moustaki M. Etiology and clinical features of viral bronchiolitis in infancy. World J. Pediatr. 2017; 13 (4): 293-299. DOI: 10.1007/s12519-017-0031-8.

6. Radzhabova G.M., Smirnova A.V., Knyazeva A.A. et al. [Clinical significance of molecular genetic approaches based on NGS technologies in a sample of patients with primary ciliary dyskinesia]. Meditsinskaya genetika. 2022; 21 (10): 38-42. DIO: 10.25557/2073-7998.2022.10.38-42 (in Russian).

7. Novak A.A., Mizernitskiy Yu.L. [Clinical and genetic spectrum of primary ciliary dyskinesia in children]. Rossiyskiy vestnik perinatologii ipediatrii. 2023; 68 (1): 39-46. DOI: 10.21508/1027-4065-2023-68-1-39-38 (in Russian).

8. Wirschell M., Olbrich H., Werner C. et al. The nexin-dynein regulatory complex subunit DRC1 is essential for motile cilia function in algae and humans. Nat. Genet. 2013; 45 (3): 262-268. DOI: 10.1038/ng.2533.

9. Kuz’mina T.N., Novak A.A, Mizernitskiy Yu.L. [Features of external respiration in patients with clinical and genetic variants of ciliary dyskinesia]. Pul’monologiya detskogo vozrasta:problemy i resheniya. 2022; (22): 34-36 (in Russian).

10. Novak A.A., Mizernitskiy Yu.L. [Clinical and genetic variants of primary ciliary dyskinesia in children]. Rossiyskiy vestnik perinatologii i pediatrii. 2022; 67 (4): 307. DOI: 10.21508/1027-4065-congress-2022 (in Russian).

11. Macri A., Wilson A.M., Shafaat O., Sharma S. Osler-Weber-Rendu disease. Updated: August 8, 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482361/

12. Mizernitskiy Yu.L., Sokolova L.V. [Lung lesions in Rendu-Osler-We-ber disease]. In: Rozinova N.N., Mizernitskiy Yu.L. [Orphan lung diseases in children]. Moscow: Medpraktika-M; 2015: 187-189 (in Russian).

13. Westermann C.J., Rosina A.F., De Vries V., De Coteau P.A. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am. J. Med. Genet. A. 2003; 116A (4): 324-328. DOI: 10.1002/ajmg.a.10002.

14. Jackson S.B., Villano N.P., Benhammou J.N. et al. Gastrointestinal manifestations of hereditary hemorrhagic telangiectasia (HHT): a systematic review of the literature. Dig. Dis. Sci. 2017; 62 (10): 2623-2630. DOI: 10.1007/s10620-017-4719-3.

15. Morgan T., McDonald J., Anderson C. et al. Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). Pediatrics. 2002; 109 (1): e12. DOI: 10.1542/peds.109.1.e12.

16. Byard R.W., Schliebs J., Koszyca B.A. Osler-Weber-Rendu syndrome-pathological manifestations and autopsy considerations. J. Forensic Sci. 2001; 46 (3): 698-701. DOI: 10.1520/JFS15025J.

17. Shovlin C.L., Jackson J.E., Bamford K.B. et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax. 2008; 63 (3): 259-266. DOI: 10.1136/thx.2007.087452.

18. Poisson A., Vasdev A., Brunelle F. et al. Acute paraplegia due to spinal arteriovenous fistula in two patients with hereditary hemorrhagic telangiectasia. Eur. J. Pediatr. 2009; 168 (2): 135-149. DOI: 10.1007/s00431-008-0863-2.

19. Robert F., Desroches-Castan A., Bailly S. et al. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J. Rare Dis. 2020; 15 (1): 4. DOI: 10.1186/s13023-019-1281-4.